Written by MarketBeatUpdated August 18, 2025 ShareLink copied to clipboard. Key Points Zevra Therapeutics' shares fell significantly after JMP Securities downgraded their price target from $19.00 to $18.00, resulting in a pre-opening price of $10.34 down from a close of $11.76. Despite the downgrade, the average rating for Zevra Therapeutics among analysts remains a "Buy" with an average price target of $23.71, bolstered by recent upgrades from other firms. Institutional investment increased, with Schroder Investment Management acquiring a new position worth $2.8 million and other firms raising their holdings, indicating continued confidence in the company's potential. Looking to export and analyze Zevra Therapeutics data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount. Like this article? Share it with a colleague. Link copied to clipboard. Featured Articles and OffersBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Trump’s national nightmare is hereFrom Porter & Company (Ad)3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Jack D. Cogen Sells 1,000,000 Shares of CoreWeave (NASDAQ:CRWV) StockBy MarketBeat | August 22, 2025Amazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025Out of 18,347 Cryptocurrencies... This is the ONLY OneFrom Crypto 101 Media (Ad)Joby Aviation: Why a Historic Flight Outweighs Analyst DowngradesBy Jeffrey Neal Johnson | August 19, 2025DBS Group Holdings Ltd (OTCMKTS:DBSDY) Announces Dividend Increase - $0.47 Per ShareBy MarketBeat | August 21, 2025 Recent Videos Stock ListsAll Stock Lists5G Biotech Blue Chip FAANG Gold Large Cap Marijuana Micro Cap Oil REITs Russell 2000 Small Cap Warren Buffett Investing ToolsCalendars and ToolsAnalyst RatingsCryptocurrency ScreenerCongressional TradingDividend IncreasesDividend CalculatorDividend CalendarEarnings AnnouncementsInsider TradesOptions Profit CalculatorPenny StocksPortfolio MonitoringShort InterestStock ComparisonsStock Market HolidaysStock Screener Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Written by MarketBeatUpdated August 18, 2025 ShareLink copied to clipboard. Key Points Zevra Therapeutics' shares fell significantly after JMP Securities downgraded their price target from $19.00 to $18.00, resulting in a pre-opening price of $10.34 down from a close of $11.76. Despite the downgrade, the average rating for Zevra Therapeutics among analysts remains a "Buy" with an average price target of $23.71, bolstered by recent upgrades from other firms. Institutional investment increased, with Schroder Investment Management acquiring a new position worth $2.8 million and other firms raising their holdings, indicating continued confidence in the company's potential. Looking to export and analyze Zevra Therapeutics data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount. Like this article? Share it with a colleague. Link copied to clipboard.
MarketBeat All Access